PT2114395E - Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações - Google Patents

Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações Download PDF

Info

Publication number
PT2114395E
PT2114395E PT78700119T PT07870011T PT2114395E PT 2114395 E PT2114395 E PT 2114395E PT 78700119 T PT78700119 T PT 78700119T PT 07870011 T PT07870011 T PT 07870011T PT 2114395 E PT2114395 E PT 2114395E
Authority
PT
Portugal
Prior art keywords
ophthalmic
oligomers
amphiphilic polymers
otic compositions
facially amphiphilic
Prior art date
Application number
PT78700119T
Other languages
English (en)
Inventor
Richard W Scott
Original Assignee
Cellceutix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellceutix Corp filed Critical Cellceutix Corp
Publication of PT2114395E publication Critical patent/PT2114395E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT78700119T 2006-12-29 2007-12-28 Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações PT2114395E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88280006P 2006-12-29 2006-12-29

Publications (1)

Publication Number Publication Date
PT2114395E true PT2114395E (pt) 2015-07-07

Family

ID=39589209

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78700119T PT2114395E (pt) 2006-12-29 2007-12-28 Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações

Country Status (12)

Country Link
US (5) US20090092574A1 (pt)
EP (1) EP2114395B1 (pt)
JP (2) JP5512279B2 (pt)
CN (3) CN102600163B (pt)
AU (1) AU2007339790B2 (pt)
CA (1) CA2674080C (pt)
DK (1) DK2114395T3 (pt)
ES (1) ES2538479T3 (pt)
HU (1) HUE025868T2 (pt)
PL (1) PL2114395T3 (pt)
PT (1) PT2114395E (pt)
WO (1) WO2008083256A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
MX2011000971A (es) * 2008-07-28 2011-06-24 Polymedix Inc Compuestos antipaludicos.
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
ITTO20090131A1 (it) * 2009-02-24 2010-08-25 Liofarmaceutici Srl Composizioni oftalmiche contenenti teicoplanina
KR20130048776A (ko) * 2010-07-07 2013-05-10 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 면역조절방법
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
WO2012158672A2 (en) * 2011-05-16 2012-11-22 Polymedix, Inc. Compounds for use in treatment of mucositis
TW201325601A (zh) * 2011-09-16 2013-07-01 Foresight Biotherapeutics Inc 安定之普維酮-碘組成物
WO2013109827A1 (en) * 2012-01-18 2013-07-25 Polymedix, Inc. Compounds and methods for treating candidiasis and aspergillus infections
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬
CA2997372A1 (en) 2015-09-03 2017-03-09 The Administrators Of The Tulane Educational Fund Compositions and methods for multipurpose disinfection and sterilization solutions
RU2019102149A (ru) * 2016-07-01 2020-08-03 Булос Энд Купер Фармасьютикалз Пти Лтд Новые антибиотики
IT201900000561A1 (it) * 2019-01-14 2020-07-14 Medivis S R L Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac
WO2021248008A1 (en) 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) * 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
SE352811B (pt) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
SE375007B (pt) 1972-11-30 1975-04-07 Pharmacia Ab
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4559343A (en) 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
US5223492A (en) 1987-10-27 1993-06-29 Nasraoui Nejib M Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them
US5190927A (en) 1991-07-09 1993-03-02 Merck & Co., Inc. High-glyceryl, low-acetyl gellan gum for non-brittle gels
CA2128612C (en) * 1992-01-23 1999-06-15 Mamoru Tomita Antimicrobial agents and method for treating products therewith
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
PL184059B1 (pl) 1994-08-30 2002-08-30 Scherer Ltd R P Urządzenie dozujące do aplikowania płynów leczniczych w postaci strumieni i/lub niewielkich kropel
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6025326A (en) 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
US5994306A (en) 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
JP3090125B2 (ja) * 1997-08-26 2000-09-18 千寿製薬株式会社 ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
ATE239003T1 (de) * 1998-08-20 2003-05-15 Univ North Carolina Dibenzothiophene derivate und ihre verwendung
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) * 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
PT1337262E (pt) * 2000-11-08 2008-10-24 Fxs Ventures Llc Soluções melhoradas para oftalmologia e para lentes de contacto com uma fonte de peróxido e um conservante catiónico polimérico
US20030021761A1 (en) 2001-01-18 2003-01-30 Geltex Pharmaceuticals, Inc. Ionene polymers and their use in treating mucositis
WO2002072007A2 (en) * 2001-03-08 2002-09-19 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers as anti-infective agents
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2003024391A2 (en) 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
JP2005529158A (ja) * 2002-05-28 2005-09-29 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 両親媒性ポリマーのコンピュータ分析および設計のための方法、システムおよびコンピュータプログラム製品
AU2003239212A1 (en) * 2002-06-13 2003-12-31 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for simulating biomembranes using coarse grain models
WO2004046109A2 (en) 2002-11-19 2004-06-03 Genzyme Corporation Ionene oligomers and polymers
JP2006521355A (ja) * 2003-03-17 2006-09-21 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア・センター・フオー・テクノロジー・トランスフアー 表面的に両親媒性のポリマー及びオリゴマーならびにそれらの使用
AU2003249114A1 (en) 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
CN1922133A (zh) * 2004-01-23 2007-02-28 宾夕法尼亚州大学理事会 表面两亲性聚芳基和聚芳基炔基聚合物和低聚物及其用途
JP5209302B2 (ja) 2004-06-15 2013-06-12 ポリメディックス、インク. ポリカチオン化合物とその使用
KR101389695B1 (ko) * 2004-07-23 2014-04-29 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 항균 공중합체 및 그 용도
EP2433627A1 (en) * 2005-02-25 2012-03-28 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
PL1704860T3 (pl) 2005-03-24 2011-04-29 Rottapharm Biotech Srl Pochodne benzamidyny do leczenia i zapobiegania zapaleniu śluzówki
WO2006122162A2 (en) 2005-05-10 2006-11-16 The University Of Chicago Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
US7951829B2 (en) 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2008137978A (ja) * 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
MX2011000971A (es) 2008-07-28 2011-06-24 Polymedix Inc Compuestos antipaludicos.
TWI478915B (zh) 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
WO2010068700A1 (en) 2008-12-10 2010-06-17 Polymedix, Inc. Antimicrobial molecules for treating multi-drug resistant and extensively drug resistant strains of mycobacterium
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
MX2012007662A (es) * 2010-01-07 2012-08-23 Polymedix Inc Compuestos anti-heparina.
TW201208677A (en) 2010-08-21 2012-03-01 Polymedix Inc Facially amphiphilic compounds, compositions, and uses thereof in treating cancer
WO2012158672A2 (en) 2011-05-16 2012-11-22 Polymedix, Inc. Compounds for use in treatment of mucositis
WO2013109827A1 (en) 2012-01-18 2013-07-25 Polymedix, Inc. Compounds and methods for treating candidiasis and aspergillus infections
WO2014093225A2 (en) 2012-12-10 2014-06-19 Cellceutix Corporation Polycyclic compounds and methods of making and using the same
WO2014093231A2 (en) 2012-12-10 2014-06-19 Cellceutix Corporation Hybrid compounds and methods of making and using the same
US9993469B2 (en) 2013-05-28 2018-06-12 Morphochem Aktiengesellschaft Für Kombinatorishe Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
JP6047203B2 (ja) 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬

Also Published As

Publication number Publication date
US20130065818A1 (en) 2013-03-14
JP2014139219A (ja) 2014-07-31
US10166232B2 (en) 2019-01-01
EP2114395A2 (en) 2009-11-11
US20190314370A1 (en) 2019-10-17
CN102600163A (zh) 2012-07-25
JP2010514798A (ja) 2010-05-06
WO2008083256A2 (en) 2008-07-10
CA2674080A1 (en) 2008-07-10
DK2114395T3 (en) 2015-06-08
AU2007339790A1 (en) 2008-07-10
CA2674080C (en) 2016-08-09
PL2114395T3 (pl) 2015-08-31
WO2008083256A3 (en) 2008-12-24
US20210093636A1 (en) 2021-04-01
JP5745666B2 (ja) 2015-07-08
CN102600163B (zh) 2014-10-01
US9192623B2 (en) 2015-11-24
ES2538479T3 (es) 2015-06-22
US20090092574A1 (en) 2009-04-09
CN102342941A (zh) 2012-02-08
EP2114395A4 (en) 2010-12-15
HUE025868T2 (en) 2016-05-30
EP2114395B1 (en) 2015-03-04
AU2007339790B2 (en) 2013-07-18
US20160228435A1 (en) 2016-08-11
CN101631543B (zh) 2011-12-07
CN101631543A (zh) 2010-01-20
JP5512279B2 (ja) 2014-06-04

Similar Documents

Publication Publication Date Title
PL2114395T3 (pl) Kompozycje oftalmiczne i douszne płaszczyznowo amfifilowych polimerów i oligomerów oraz ich zastosowania
ZA200901386B (en) Masterbatch and polymer composition
GB0911139D0 (en) Directly photodefinable polymer compositions and methods thereof
PL2281013T3 (pl) Sposoby regulacji rozkładu ciężaru cząsteczkowego polimerów i ich składu
EP2024476A4 (en) COMPOSITIONS WITH LOW-DP POLYMERIZED TENSIDES AND METHOD OF USE
EP2012803A4 (en) POLYMER COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
EP2187980A4 (en) HYDROGEL POLYMER COMPOSITIONS AND METHODS
EP2128196A4 (en) POLYMERIC COMPOSITION AND APPLICATION THEREOF
EP1933881A4 (en) SOLID POLYMER DISPENSING COMPOSITIONS AND APPLICATION METHOD THEREFOR
EP1848410A4 (en) COMPOSITIONS FOR DISPENSING POLYMER PARTICLES AND APPLICATION METHOD THEREFOR
PL3050568T3 (pl) Sposoby i kompozycje do przedłużonego uwalniania chromu
EP2235090A4 (en) MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME
EP2134543A4 (en) STABILIZER POLYMER AND COATING COMPOSITIONS THEREOF
EP1874844A4 (en) HYPERRAMIFIED POLYMERS AND THEIR APPLICATIONS
IL179296A0 (en) Amphiphilic polymer compositions and their use
EP2079844A4 (en) SYNTHESIS OF INIMERS AND HYPERBRANCHED POLYMERS
EP2180879A4 (en) NON-TEXTILE POLYMERIC COMPOSITIONS AND METHODS
EP1858535A4 (en) COMPOSITIONS WITH ACTINIDIA AND METHOD OF USE THEREOF
AU2007291030A8 (en) Novel compositions and methods
GB0622399D0 (en) Novel compositions and uses thereof
EP2021448A4 (en) COMPOSITIONS WITH POLYMERIZED LOW-DP TENSIDES AND METHOD OF USE THEREOF
EP2021447A4 (en) COMPOSITIONS COMPRISING POLYMERIZED LOW-DP SURFACTANTS AND METHODS OF USE THEREOF
GB0715428D0 (en) Compositions and uses thereof
GB0622400D0 (en) Novel compositions and uses thereof
GB0701170D0 (en) Compositions and uses thereof